Iovance Biotherapeutics (2LB) Stock Forecast & Price Target
19 Followers
2LB Analyst Ratings
Strong Buy
8Buy2Hold0Sell
Based on 10 analysts giving stock ratings to Iovance Biotherapeutics in the past 3 months
2LB Stock 12 Month Forecast
Average Price Target
EUR 13.20▲(76.27% Upside)Based on 10 Wall Street analysts offering 12 month price targets for Iovance Biotherapeutics in the last 3 months. The average price target is EUR 13.20 with a high forecast of EUR 17.84 and a low forecast of EUR 7.14. The average price target represents a 76.27% change from the last price of EUR 7.49.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 17.84
AverageEUR 13.20
LowEUR 7.14
Highest Price TargetHighestEUR 17.84Average Price TargetEUR 13.20Lowest Price TargetLowestEUR 7.14
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Etzer Darout | Barclays | EUR 16.06→EUR 16.95 | buy | 126.29%Upside | Reiterated | 11/06/26 | ||
| Reni Benjamin | Citizens JMP | EUR 7.14→EUR 10.70 | buy | 42.92%Upside | Reiterated | 11/06/26 | ||
| Joseph Pantginis | H.C. Wainwright | EUR 17.84 | buy | 138.20%Upside | Reiterated | 11/05/26 | ||
| David Dai | UBS | EUR 6.24→EUR 7.14 | hold | -4.72%Downside | Assigned | 11/03/26 | ||
| Colleen M. Kusy | Robert W. Baird | EUR 9.81→EUR 8.03 | hold | 7.19%Upside | Reiterated | 10/30/26 | ||
| Yanan Zhu | Wells Fargo | EUR 16.06 | buy | 114.38%Upside | Reiterated | 10/29/26 | ||
| Andrew Tsai | Jefferies | EUR 17.84 | buy | 138.20%Upside | Reiterated | 10/23/26 | ||
| Nicholas Lorusso | TD Cowen | EUR 8.92→EUR 14.27 | buy | 90.56%Upside | Reiterated | 09/29/26 | ||
| Andrea Newkirk | Goldman Sachs | EUR 13.38 | buy | 78.65%Upside | Initiated | 09/24/26 | ||
| Salim Syed | Mizuho Securities | EUR 8.92→EUR 9.81 | buy | 31.01%Upside | Reiterated | 08/17/26 | ||
| Geulah Livshits | Chardan Capital | EUR 12.49 | buy | 66.74%Upside | Reiterated | 05/07/26 | ||
| Asthika Goonewardene | Leerink Partners | ― | hold | ― | Reiterated | 02/25/26 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Etzer DaroutBarclays | BuyReiteratedEUR 16.06→EUR 16.95 | 11/06/26 | 126.29%Upside | ||
| Reni BenjaminCitizens JMP | BuyReiteratedEUR 7.14→EUR 10.70 | 11/06/26 | 42.92%Upside | ||
| Joseph PantginisH.C. Wainwright | BuyReiteratedEUR 17.84 | 11/05/26 | 138.20%Upside | ||
| David DaiUBS | HoldAssignedEUR 6.24→EUR 7.14 | 11/03/26 | -4.72%Downside | ||
| Colleen M. KusyRobert W. Baird | HoldReiteratedEUR 9.81→EUR 8.03 | 10/30/26 | 7.19%Upside | ||
| Yanan ZhuWells Fargo | BuyReiteratedEUR 16.06 | 10/29/26 | 114.38%Upside | ||
| Andrew TsaiJefferies | BuyReiteratedEUR 17.84 | 10/23/26 | 138.20%Upside | ||
| Nicholas LorussoTD Cowen | BuyReiteratedEUR 8.92→EUR 14.27 | 09/29/26 | 90.56%Upside | ||
| Andrea NewkirkGoldman Sachs | BuyInitiatedEUR 13.38 | 09/24/26 | 78.65%Upside | ||
| Salim SyedMizuho Securities | BuyReiteratedEUR 8.92→EUR 9.81 | 08/17/26 | 31.01%Upside | ||
| Geulah LivshitsChardan Capital | BuyReiteratedEUR 12.49 | 05/07/26 | 66.74%Upside | ||
| Asthika GoonewardeneLeerink Partners | HoldReiterated | 02/25/26 | ― |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Iovance Biotherapeutics
3 Months
Success Rate13/16 ratings generated profit
81%
Average Return
+24.34%
Copying Joseph Pantginis's trades and holding each position for 3 Months would result in 81.25% of your transactions generating a profit, with an average return of +24.34% per trade.
1 Year
Success Rate13/16 ratings generated profit
81%
Average Return
+139.37%
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +139.37% per trade.
2 Years
Success Rate13/16 ratings generated profit
81%
Average Return
+169.18%
Copying Joseph Pantginis's trades and holding each position for 2 Years would result in 81.25% of your transactions generating a profit, with an average return of +169.18% per trade.
2LB Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 9 | 7 | 3 | 5 | 6 |
| Buy | 1 | 4 | 11 | 15 | 11 |
| Hold | 0 | 2 | 2 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 10 | 13 | 16 | 24 | 20 |
In the current month, 2LB has received 17 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 2LB average Analyst price target in the past 3 months is 13.20.
2LB Financial Forecast
HighEUR -0.04
ConsensusEUR -0.04
LowEUR -0.05
2LB Earnings Forecast
Next quarter’s earnings estimate for 2LB is -EUR 0.04 with a range of -EUR 0.05 to -EUR 0.04. The previous quarter’s EPS was -EUR 0.04. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 120M
ConsensusEUR 115M
LowEUR 111M
2LB Sales Forecast
Next quarter’s sales forecast for 2LB is EUR 114.70M with a range of EUR 110.79M to EUR 120.30M. The previous quarter’s sales results were EUR 108.36M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
2LB Stock Forecast FAQ
What is DE:2LB’s average 12-month price target, according to analysts?
Based on analyst ratings, Iovance Biotherapeutics’s 12-month average price target is €13.20.
What is DE:2LB’s upside potential, based on the analysts’ average price target?
Iovance Biotherapeutics has 76.27% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Iovance Biotherapeutics a Buy, Sell or Hold?
Iovance Biotherapeutics has a consensus rating of Strong Buy, which is based on 8 buy ratings, 2 hold ratings and 0 sell ratings.
What is Iovance Biotherapeutics’s share price target?
The average share price target for Iovance Biotherapeutics is €13.20. This is based on 10 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €17.84, and the lowest forecast is €7.14. The average share price target represents a 76.27% increase from the current price of €7.49.
What do analysts say about Iovance Biotherapeutics?
Iovance Biotherapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Street analysts.
How can I buy shares of Iovance Biotherapeutics?
To buy shares of DE:2LB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
